J9057 Injection., copanlisib, 1 milligrams
Also known as: copanlisib, Aliqopa
Intravenous injection of copanlisib, a class I phosphoinositide 3-kinase inhibitor, dosed per 1 milligram.
In Plain Language
signaling pathway inhibitor; lymphoma-targeting drug
Clinical Context
Used for relapsed follicular lymphomas as monotherapy or in combination. Selectively inhibits PI3K signaling in lymphoid malignancies.
RVU Information
CPT J9057 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.
Billing & Documentation
J-codes represent drugs administered by a healthcare provider (not self-administered). Documentation must include the drug name, dosage, route of administration, and medical necessity. Most payers require the National Drug Code (NDC) on the claim. Bill the appropriate administration code (96365-96379) in addition to the drug code.
Specialties
Frequently Asked Questions
What is CPT code J9057?
CPT J9057 (Injection., copanlisib, 1 milligrams) is a J Codes (Drugs) code. Intravenous injection of copanlisib, a class I phosphoinositide 3-kinase inhibitor, dosed per 1 milligram.
How is J9057 administered?
CPT J9057 is administered by a healthcare provider, typically via injection or infusion. Used for relapsed follicular lymphomas as monotherapy or in combination. Selectively inhibits PI3K signaling in lymphoid malignancies. It is used by Hematology/Oncology, Medical Oncology.
When is CPT J9057 used?
Used for relapsed follicular lymphomas as monotherapy or in combination. Selectively inhibits PI3K signaling in lymphoid malignancies.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.